Sentinel lymph node as a target of molecular diagnosis of lymphatic micrometastasis and local immunoresponse to malignant cells
- 2 January 2008
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 99 (3), 441-450
- https://doi.org/10.1111/j.1349-7006.2007.00672.x
Abstract
The sentinel lymph node (SLN) is defined as the lymph node(s) first receiving lymphatic drainage from the site of the primary tumor. The histopathological status of SLN is one of the most significant predictors of recurrence and overall survival for most clinical stage I/II solid tumors. Recent progress in molecular techniques has demonstrated the presence of micrometastatic tumor cells in SLN. There is now a growing body of data to support the clinical relevance of SLN micrometastasis in a variety of solid tumors. Increasing the sensitivity of occult tumor cell detection in the SLN, using molecular-based analysis, should enable a more accurate understanding of the clinical significance of various patterns of micrometastatic nodal disease. The establishment of metastasis to SLN might not be simply reflected by the flow dynamics of lymphatic fluid that drains from the primary site to the SLN, and the transportation of viable cancer cells. Recent studies have demonstrated that primary tumors can actively induce lymphangiogenesis and promote SLN metastasis. Moreover chemokine receptors in tumor cells may facilitate organ-specific tumor metastasis in many human cancers and some experimental models. In contrast, recent clinical and preclinical studies regard SLN as the first lymphoid organ to respond to tumor antigenic stimulation. SLN dramatically show morphological, phenotypical and functional changes that indicate immune suppression by tumor cells. The immune suppression in SLN results in failure of prevention or eradication of tumor metastasis. The mechanism of immunomodulation remains unclear; however, several regulatory molecules produced by tumor cells and tumor-associated macrophages or lymphocytes are likely to be responsible for inducing the immune suppression in SLN. Further studies may develop a novel immunotherapy that overcomes tumor-induced immune suppression and can prevent or eradicate SLN metastasis.Keywords
This publication has 117 references indexed in Scilit:
- Mechanisms of local immunosuppression in cutaneous melanomaBritish Journal of Cancer, 2007
- Dissemination and growth of cancer cells in metastatic sitesNature Reviews Cancer, 2002
- National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000JNCI Journal of the National Cancer Institute, 2001
- The Sentinel Node in Breast Cancer — A Multicenter Validation StudyThe New England Journal of Medicine, 1998
- Micrometastases and Survival in Stage II Colorectal CancerThe New England Journal of Medicine, 1998
- Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trialThe Lancet, 1998
- Lymphatic Mapping and Sentinel Lymphadenectomy for Breast CancerAnnals of Surgery, 1994
- Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery, 1992
- Ten-Year Results of a Randomized Clinical Trial Comparing Radical Mastectomy and Total Mastectomy with or without RadiationThe New England Journal of Medicine, 1985
- Inefficacy of Immediate Node Dissection in Stage 1 Melanoma of the LimbsThe New England Journal of Medicine, 1977